English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Purpose Severe respiratory illnesses in newborns are a leading cause of pediatric death worldwide, resulting in over 1 million deaths annually; 99% of these deaths occur in lowto middleincome countries. Bubble Continuous Positive Airway Pressure (bCPAP) is a simple, proven, and widely used therapy for infants in respiratory distress. However, infants with more serious respiratory illnesses need more advanced therapy, traditionally provided with a mechanical ventilator. In many settings, current treatment options for newborns with these severe illnesses are too expensive, require highly skilled operators, and fail during power outages that are common in the developing world. Product We aim to develop highquality, lowcost, lowpower, and easytouse respiratory equipment for patients in emerging markets. Our patentpending NeoVent is a oneconnection addon to existing bCPAP setups to provide the next level of care: noninvasive bilevel pressure ventilation. Our easytouse design has only one moving piece and does not require continuous electricity. As with a traditional ventilator, the clinician can use NeoVent to set two independent pressure levels and the rate cycling between them. We anticipate the NeoVent can be manufactured for less than 1/100th the manufacturing cost of traditional ventilators. Next Steps We have completed preclinical studies demonstrating device efficacy and are currently preparing to launch our firstinhuman NeoVent safety study, followed by a larger study of efficacy. After clinical validation, we plan to wholesale the device as a oneconnection addon to companies with developed distribution channels and customer bases

NeoVent: Global Low Cost, Low-Tech Respiratory Support for Infants